

Middle East and Africa Insulin Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029

Market Report | 2024-02-17 | 112 pages | Mordor Intelligence

AVAILABLE LICENSES:

- Single User License \$4750.00
- Team License (1-7 Users) \$5250.00
- Site License \$6500.00
- Corporate License \$8750.00

Report description:

The Middle East and Africa Insulin Delivery Devices Market size is estimated at USD 1.96 billion in 2024, and is expected to reach USD 2.27 billion by 2029, growing at a CAGR of 2.99% during the forecast period (2024-2029).

The COVID-19 pandemic has substantially impacted the Middle East and Africa Insulin Delivery Devices Market. Type-1 diabetes patients are impacted more during Covid-19. People with diabetes are having a weak immune system so, with COVID-19, the immune system gets weaker very fast. People with diabetes will have more chances to get into serious complications rather than normal people. The manufacturers of Insulin delivery devices have taken care during COVID-19 to deliver insulin delivery devices to diabetes patients with the help of local governments. Novo Nordisk stated on their website that 'Since the start of COVID-19, our commitment to patients, our employees and the communities where we operate has remained unchanged, we continue to supply our medicines and devices to people living with diabetes and other serious chronic diseases, safeguard the health of our employees, and take actions to support doctors and nurses as they work to defeat COVID-19.' Doctors around the world suggested diabetes patients should check their diabetes levels more often to be careful and the intake of medicine has increased, which lead to an increase in the usage of insulin delivery devices.

An insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen. Insulin infusion pumps reduce the large swings in blood glucose levels, lessen pain, and deliver more accurately than injections. The scheduling of meal timings is not required when using pumps. This makes infusion pumps more user-friendly for patients. Insulin therapy is also known as continuous subcutaneous insulin infusion (CSII). It is an efficient and flexible method of insulin delivery.

Technological advancements have increased over the period in Insulin delivery devices for safer and more accurate administration of insulin. In 2021, Medtronic launched an Extended infusion set that leverages advanced materials that help

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

reduce insulin preservative loss and maintains insulin flow and stability. The set is compatible with all MiniMed 600 and 700 series insulin pumps. The new tubing connector improves the physical and chemical stability of insulin, reliability of infusion site performance, and reduces the risk of infusion set occlusion. In addition to the new infusion set, the Medtronic Extended reservoir is also tested and approved to keep insulin stable and safely used for up to 7 days.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Middle East And Africa Insulin Delivery Devices Market Trends

The Insulin Pumps Segment is expected to witness the highest growth rate over the forecast period

The insulin pump segment is expected to register the highest growth rate of about 4.8% over the forecast period.

An insulin pump is a small battery-operated electronic device about the size of a pager or small mobile phone. The rapid-acting insulin is delivered via an infusion set that is inserted under the skin, i.e., subcutaneously. The device delivers insulin in two ways: basal (delivering small amounts of insulin continuously to maintain cell function) and bolus (delivering a dose of insulin on demand to account for the carbohydrates in meals or to correct high blood glucose levels). An insulin pump is worn 24 hours a day but can be taken off for up to two hours when required.

Data can be uploaded from insulin pumps via web-based software. The data relating to glucose concentrations and insulin delivery can be reviewed by the health professional with the patient. Randomized controlled trials have reported improvements in glycemic control using insulin pump therapy compared to multiple daily injections. These include reductions in blood glucose, reduced hypoglycemia, lower glycated hemoglobin, lower insulin requirements, and improved quality of life. Type-1 diabetic patients need to check their blood glucose levels at regular intervals, monitor their blood glucose levels, and adjust the insulin dosing accordingly to maintain optimum glucose levels in the body.

In the Middle East and African region, in recent years, the rate of diabetes has reached an all-time high, mainly due to lifestyle changes. Governments in the Middle East have identified the threat of diabetes and started to respond with various policies, initiatives, and programs. Six out of 15 countries in this region still do not have a national operational action policy for diabetes. Many countries still do not have a national strategy to reduce overweight, obesity, and physical inactivity, which are important risk factors for diabetes. Most countries have fully implemented national diabetes treatment guidelines. However, constant measures are being taken to minimize diabetic complications; therefore, owing to the aforesaid factors, the growth of the studied market is anticipated over the forecast period.

Iran is expected to dominate the Middle East and Africa Insulin Delivery Devices Market over the forecast period

Iran holds the highest market share in the Middle East and Africa insulin delivery devices market and is expected to register a CAGR of over 3.8% over the forecast period.

Diabetes is a serious public health concern in Iran, the Middle East's second-largest country, due to its high prevalence rate, growing occurrence rate, and economic impact. Diabetes-related mortality in Iran continues to rise; the age-standardized death rate from diabetes has risen throughout the years. Diabetes has significant economic consequences for the country. Diabetes, in addition to its high direct healthcare costs, is a significant risk factor for other chronic illnesses, such as cardiovascular disease.

Diabetes complications accounted for USD 412 (49%) of the USD 843 per capita cost of diabetes in 2021. Yazd, a world heritage city located in the center of Iran, has one of the highest recorded prevalences of diabetes mellitus in Iran. Other cities in Iran have varying levels of diabetes awareness. For example, in Kerman, a province south of Yazd, the prevalence of undiagnosed diabetes

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

is only 2.7%, but it is 25% in northern Iran. Despite the widespread availability of drugs and insulin coverage in Iran, the estimated national control of hyperglycemia, hyperlipidemia, and hypertension (particularly among young men and women) remains inadequate.

However, the roll-out of many new products, increasing international research collaborations in technological advancement, and increasing awareness about diabetes among people are some of the market opportunities for the players in the market.

Middle East And Africa Insulin Delivery Devices Industry Overview

The Middle East and Africa insulin delivery devices market is moderately consolidated in nature due to the presence of only a few major companies like Novo Nordisk, Sanofi, Eli Lilly and Company, Medtronic, Insulet, Ypsomed, Becton Dickinson & Company, etc. operating globally and other regional players.

Additional Benefits:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

Table of Contents:

1 INTRODUCTION

- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
- 4.4 Porter's Five Forces Analysis
 - 4.4.1 Bargaining Power of Suppliers
 - 4.4.2 Bargaining Power of Consumers
 - 4.4.3 Threat of New Entrants
 - 4.4.4 Threat of Substitute Products and Services
 - 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

- 5.1 Type
 - 5.1.1 Insulin Pumps
 - 5.1.1.1 Insulin Pump Device
 - 5.1.1.2 Reservoir
 - 5.1.1.3 Infusion Sets
 - 5.1.2 Insulin Syringes
 - 5.1.3 Insulin Disposable Pens
 - 5.1.4 Insulin Cartridges in Reusable Pens

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.1.5 Jet Injectors
- 5.2 Geography
 - 5.2.1 Egypt
 - 5.2.2 Iran
 - 5.2.3 Oman
 - 5.2.4 Rest of Middle East and Africa
 - 5.2.5 Saudi Arabia
 - 5.2.6 South Africa

6 MARKET INDICATORS

- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population

7 COMPETITIVE LANDSCAPE

7.1 COMPANY PROFILES

- 7.1.1 Novo Nordisk A/S
- 7.1.2 Sanofi
- 7.1.3 Eli Lilly and Company
- 7.1.4 Medtronic PLC
- 7.1.5 Insulet Corporation
- 7.1.6 Ypsomed
- 7.1.7 Becton Dickinson and Company

7.2 COMPANY SHARE ANALYSIS

- 7.2.1 Novo Nordisk A/S
- 7.2.2 Sanofi
- 7.2.3 Eli Lilly and Company
- 7.2.4 Other Company Share Analyses

8 MARKET OPPORTUNITIES AND FUTURE TRENDS

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Middle East and Africa Insulin Delivery Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2018 - 2029

Market Report | 2024-02-17 | 112 pages | Mordor Intelligence

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User License	\$4750.00
	Team License (1-7 Users)	\$5250.00
	Site License	\$6500.00
	Corporate License	\$8750.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-02-28"/>
		Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

